248 related articles for article (PubMed ID: 12606507)
21. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
22. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
Yatagai T; Nakamura T; Nagasaka S; Kusaka I; Ishikawa SE; Yoshitaka A; Ishibashi S
Diabetes Res Clin Pract; 2004 Jan; 63(1):19-26. PubMed ID: 14693409
[TBL] [Abstract][Full Text] [Related]
23. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Kosegawa I; Chen S; Awata T; Negishi K; Katayama S
Clin Exp Hypertens; 1999 Apr; 21(3):199-211. PubMed ID: 10225476
[TBL] [Abstract][Full Text] [Related]
25. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
Gavin LA; Barth J; Arnold D; Shaw R
Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
[TBL] [Abstract][Full Text] [Related]
26. Adiponectin and its response to thiazolidinediones are associated with insulin-mediated glucose metabolism in type 2 diabetic patients and their first-degree relatives.
Hulstrøm V; Højlund K; Vinten J; Beck-Nielsen H; Levin K
Diabetes Obes Metab; 2008 Nov; 10(11):1019-28. PubMed ID: 18284435
[TBL] [Abstract][Full Text] [Related]
27. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of troglitazone action in type 2 diabetes.
Petersen KF; Krssak M; Inzucchi S; Cline GW; Dufour S; Shulman GI
Diabetes; 2000 May; 49(5):827-31. PubMed ID: 10905493
[TBL] [Abstract][Full Text] [Related]
30. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
31. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
[TBL] [Abstract][Full Text] [Related]
32. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase.
Huypens P; Quartier E; Pipeleers D; Van de Casteele M
Eur J Pharmacol; 2005 Aug; 518(2-3):90-5. PubMed ID: 16039647
[TBL] [Abstract][Full Text] [Related]
33. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
Ciaraldi TP; Oh DK; Christiansen L; Nikoulina SE; Kong AP; Baxi S; Mudaliar S; Henry RR
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E891-8. PubMed ID: 16757548
[TBL] [Abstract][Full Text] [Related]
34. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
35. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
Walli R; Michl GM; Mühlbayer D; Brinkmann L; Goebel FD
Res Exp Med (Berl); 2000 Apr; 199(5):253-62. PubMed ID: 10815754
[TBL] [Abstract][Full Text] [Related]
36. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
37. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
38. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
39. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.
Phillips SA; Kung J; Ciaraldi TP; Choe C; Christiansen L; Mudaliar S; Henry RR
Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E767-73. PubMed ID: 19622782
[TBL] [Abstract][Full Text] [Related]
40. The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB
Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
